Seems a little odd that they were able to raise 20M,
selling 1.6M shares at $12/share just a couple weeks
ago and now GZMO is only worth $7 1/2 today.
On the other hand, my TGEN sold shares and I watched
that stock get halved too. Strange stuff--but I guess
you just have to roll with it.
Here is the link for the quarterly call of two weeks ago.
nasdaq.com
Maybe "no update on the German data" put somebody
out there in a mood to sell this one?
I think this is the correct abstract from ASCO:
asco.org
Well, just another one to look at while the price is down,
I thought the call was pretty decent--but now I'm listening
a second time to figure out what I missed. It certainly is
strange that Maderis would paint such a glowing picture of
the year ahead, and now GZMO is down, what, about 40% since
she spoke in that public forum. I'd hate to think somebody
has inside information of crummy data and such.
I think Spekulatius has it right when he looks at
marketcap, hope so--that is mostly all I try to do.
Does it seem likely that Genzyme would put together an
oncology division, allocate to it SAGE and a chunk of
aaAT3, the p53 programs, and the fusion vaccines, and
then let it rot on the vine for a crummy 100M marketcap?
At the very least they can reel it back in, and you get
your money back. At best these trackers stay separate
from papa Genzyme and you wait for something to come
through. Could take a few years tho. |
